Most recent update: Thursday, November 30, 2017 - 11:56

Bariatric News - Cookies & privacy policy

You are here

Acquisition

Ethicon completes Torax Medical acquisition

The Linx Reflux Management System offers patients a clinically proven, safe, effective and durable alternative to the anatomy-altering laparoscopic nissen fundoplication (LNF)

Ethicon has completed its acquisition of Torax Medical, a privately held medical device company that manufactures and markets the Linx Reflux Management System for the surgical treatment of gastroesophageal reflux disease (GERD). Ethicion said this acquisition is aligned with its strategy of expanding its portfolio of minimally invasive options for patients suffering from prevalent and serious medical conditions. Financial terms of the transaction have not been disclosed.

“Millions of patients continue to suffer from GERD symptoms even when taking high dosages of medication to treat the acid reflux and are left with limited choices to improve their symptoms,” said Michael del Prado, Group Company Chair of Ethicon. “This novel technology offers patients an attractive minimally invasive surgical alternative, that preserves gastric anatomy, establishes normal physiological function, and is reversible.”

According to the company, the Linx Reflux Management System offers patients a clinically proven, safe, effective and durable alternative to the anatomy-altering laparoscopic nissen fundoplication (LNF). The system is a small implant comprised of interlinked titanium beads with magnetic cores. The magnetic attraction between the beads augments the oesophageal sphincter’s barrier function to prevent reflux.

The magnetic attraction between the beads helps the lower oesophageal sphincter (LOS) resist opening to gastric pressures, preventing reflux from the stomach into the oesophagus. Swallowing forces temporarily break the magnetic bond, allowing food and liquid to pass normally into the stomach. Magnetic attraction closes the LOS immediately after swallowing, restoring the body’s natural barrier to reflux.

“Torax and Ethicon share a vision for the transformational role that our products can have in advancing patient care,” said Todd Berg, CEO and President of Torax Medical. “We are excited to join together to expand patient access to the clinical benefits of LINX.”

Linx is currently used by physicians in over 300 hospitals in the US and Europe. This acquisition is consistent with Ethicon’s strategy of advancing innovation and investing in areas of unmet medical needs such as oesophageal health.

Financial terms of the transaction have not been disclosed. 

Want more stories like this? Subscribe to Bariatric News!

Bariatric News
Keep up to date! Get the latest news in your inbox. NOTE: Bariatric News WILL NOT pass on your details to 3rd parties. However, you may receive ‘marketing emails’ sent by us on behalf of 3rd parties.